Carlo Palmieri

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. pmc A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer
    Carlo Palmieri
    Charing Cross Hospital, London, United Kingdom
    Oncologist 17:1429-e47. 2012
  2. pmc Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse
    C Palmieri
    Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK
    Br J Cancer 107:732-8. 2012
  3. pmc Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas
    C Palmieri
    Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK
    Br J Cancer 107:375-81. 2012
  4. doi request reprint Ethnicity and breast cancer research
    Carlo Palmieri
    Cancer Research UK Laboratories, Department of Cancer Medicine, Imperial College, London W12 0NN, UK
    Lancet 372:188-9. 2008
  5. doi request reprint Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era
    Carlo Palmieri
    Cancer Research UK Laboratories, Division of Cancer, Imperial College London, UK
    Clin Breast Cancer 11:93-102. 2011
  6. pmc Serum 25-hydroxyvitamin D levels in early and advanced breast cancer
    C Palmieri
    Cancer Research UK Laboratories, Department of Cancer Medicine, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    J Clin Pathol 59:1334-6. 2006
  7. ncbi request reprint Placental-site trophoblastic tumour: an unusual presentation with bilateral ovarian involvement
    Carlo Palmieri
    Department of Cancer Medicine, Charing Cross Hospital, London, UK
    Lancet Oncol 6:59-61. 2005
  8. doi request reprint Rechallenging with anthracyclines and taxanes in metastatic breast cancer
    Carlo Palmieri
    Cancer Research UK Laboratories, Department of Oncology, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London W12 ONN, UK
    Nat Rev Clin Oncol 7:561-74. 2010
  9. ncbi request reprint Managing malignant disease in patients with porphyria
    C Palmieri
    Department of Cancer Medicine, Faculty of Medicine, Imperial College London, UK
    QJM 97:115-26. 2004
  10. doi request reprint Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer
    Carlo Palmieri
    Cancer Research UK Laboratories, Division of Cancer, Imperial College, Du Cane Road, London W12 0NN, UK
    Expert Rev Anticancer Ther 11:179-83. 2011

Detail Information

Publications44

  1. pmc A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer
    Carlo Palmieri
    Charing Cross Hospital, London, United Kingdom
    Oncologist 17:1429-e47. 2012
    ..Docetaxel and vinorelbine have demonstrated efficacy in the treatment of metastatic breast cancer (MBC). This prospective feasibility study compared the efficacy of these two treatments in MBC...
  2. pmc Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse
    C Palmieri
    Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK
    Br J Cancer 107:732-8. 2012
    ..It has properties consistent with a tumour suppressor; however, other data suggest that CEBPδ may be involved in the metastatic process...
  3. pmc Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas
    C Palmieri
    Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK
    Br J Cancer 107:375-81. 2012
    ..Calcium ion channels are key in controlling the intracellular calcium, and little is known about their role in human cancer...
  4. doi request reprint Ethnicity and breast cancer research
    Carlo Palmieri
    Cancer Research UK Laboratories, Department of Cancer Medicine, Imperial College, London W12 0NN, UK
    Lancet 372:188-9. 2008
  5. doi request reprint Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era
    Carlo Palmieri
    Cancer Research UK Laboratories, Division of Cancer, Imperial College London, UK
    Clin Breast Cancer 11:93-102. 2011
    ..This study explores the use and nonuse of AT in early breast cancer, as well as the efficacy in a neoadjuvant and adjuvant population, within a routine clinical setting...
  6. pmc Serum 25-hydroxyvitamin D levels in early and advanced breast cancer
    C Palmieri
    Cancer Research UK Laboratories, Department of Cancer Medicine, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    J Clin Pathol 59:1334-6. 2006
    ..Serum levels of 1,25(OH)(2)D are higher in normal women than in patients with primary breast cancer...
  7. ncbi request reprint Placental-site trophoblastic tumour: an unusual presentation with bilateral ovarian involvement
    Carlo Palmieri
    Department of Cancer Medicine, Charing Cross Hospital, London, UK
    Lancet Oncol 6:59-61. 2005
  8. doi request reprint Rechallenging with anthracyclines and taxanes in metastatic breast cancer
    Carlo Palmieri
    Cancer Research UK Laboratories, Department of Oncology, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London W12 ONN, UK
    Nat Rev Clin Oncol 7:561-74. 2010
    ..This Review examines the evidence for rechallenging with both anthracyclines and taxanes, and highlights the issues that need to be examined in the context of future clinical trials...
  9. ncbi request reprint Managing malignant disease in patients with porphyria
    C Palmieri
    Department of Cancer Medicine, Faculty of Medicine, Imperial College London, UK
    QJM 97:115-26. 2004
    ..We briefly review the biochemical basis, clinical features and current management of porphyria in cancer patients...
  10. doi request reprint Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer
    Carlo Palmieri
    Cancer Research UK Laboratories, Division of Cancer, Imperial College, Du Cane Road, London W12 0NN, UK
    Expert Rev Anticancer Ther 11:179-83. 2011
    ....
  11. doi request reprint Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab
    Laura M Kenny
    Department of Cancer Medicine, Imperial College, London, UK
    Clin Cancer Res 16:4236-45. 2010
    ..This study sought to evaluate the reproducibility of [(11)C]choline-positron emission tomography and the effect of trastuzumab in breast cancer...
  12. doi request reprint Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography
    Kaiyumars B Contractor
    Department of Oncology, Imperial College London, London, UK
    Nucl Med Commun 32:997-1004. 2011
    ..Furthermore, we evaluated CHKα and the Ki67-labelling index (LIKi67) in tumour biopsies...
  13. doi request reprint Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography
    Laura M Kenny
    Department of Oncology, Imperial College London, London, United Kingdom
    Clin Cancer Res 15:6649-57. 2009
    ..In this study, we assessed for the first time the altered pharmacokinetics of FLT in patients following administration of capecitabine, a drug whose mode of action has been reported to include TS inhibition...
  14. doi request reprint Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome
    Jonathan Krell
    Department of Medical Oncology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
    Clin Breast Cancer 11:153-60. 2011
    ..The purpose of this study is to evaluate the response to and benefit of first-line metastatic treatment (including re-exposure to trastuzumab) for patients relapsing after exposure to adjuvant trastuzumab (AT)...
  15. doi request reprint [11C]choline positron emission tomography in estrogen receptor-positive breast cancer
    Kaiyumars B Contractor
    Department of Oncology, Imperial College, London, United Kingdom
    Clin Cancer Res 15:5503-10. 2009
    ....
  16. doi request reprint Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience
    Jayson Wang
    Department of Cancer Medicine, Imperial College London, Charing Cross Hospital, London, UK
    Breast J 15:247-53. 2009
    ..This data suggest fulvestrant is well tolerated and is a useful treatment option in patients with advanced breast cancer who progress on prior endocrine treatment...
  17. doi request reprint Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy
    Kaiyumars Contractor
    Faculty of Medicine, Imperial College London, London, UK
    Phys Med Biol 57:3419-33. 2012
    ..FLT-PET and FLT-PET(KSF) detected changes in proliferation in liver metastases...
  18. doi request reprint Role of fulvestrant in the management of postmenopausal breast cancer
    Jonathan Krell
    Department of Surgery and Cancer, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 ONN, UK
    Expert Rev Anticancer Ther 11:1641-52. 2011
    ..Fulvestrant is a well-tolerated drug and its toxicities will also be reviewed. The optimal position of fulvestrant in sequential endocrine therapy has yet to be defined...
  19. pmc FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer
    Richard E Francis
    Cancer Research UK Labs, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK
    Int J Oncol 35:57-68. 2009
    ..Our results indicate that the HER2 receptor regulates the expression of the FoxM1 transcription factor, which has a role in breast cancer development...
  20. doi request reprint TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis
    Matthew P Caley
    Department of Surgery and Cancer, Imperial College London, UK
    J Pathol 226:775-83. 2012
    ..The findings of this study provide a rationale for targeting collagen remodelling by Endo180 in bone metastases and other collagen matrix pathologies...
  21. pmc Breast cancer metastasizing to the tongue
    Pratap Neelakantan
    Department of Medical Oncology, Charing Cross Hospital, London, UK
    Can J Surg 51:E63-4. 2008
  22. ncbi request reprint Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis
    Scott P Fraser
    Neuroscience Solutions to Cancer Research Group, Department of Biological Sciences, Imperial College London, UK
    Clin Cancer Res 11:5381-9. 2005
    ..The purpose of this study was to investigate voltage-gated Na(+) channel (VGSC) expression and its possible role in human breast cancer...
  23. ncbi request reprint Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia
    Tony Dhillon
    Department of Medical Oncology, Charing Cross Hospital Campus of Imperial College, Fulham Palace Road, London W6 8RF, UK
    J Reprod Med 51:879-87. 2006
    ..To evaluate the usefulness of positron emission tomography with 18-fluorodeoxyglucose (18FDG-PET) in locating residual or relapsed gestational trophoblastic neoplasia (GTN)...
  24. ncbi request reprint Placental site trophoblastic tumour arising from a partial hydatidiform mole
    Carlo Palmieri
    Department of Cancer Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
    Lancet 366:688. 2005
  25. ncbi request reprint Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast
    Sean R McLean
    Department of Medical Oncology, Charring Cross Hospital, London, UK
    J Cutan Pathol 34:934-8. 2007
    ..In addition, clinical response to FEC by metastatic DEA has not been previously documented, and this therapeutic regimen warrants further investigation...
  26. doi request reprint A 2009 update on the treatment of patients with hormone receptor-positive breast cancer
    Susan J Cleator
    Breast Unit, St Mary s Hospital, Imperial College Healthcare NHS Trust, United Kingdom
    Clin Breast Cancer 9:S6-S17. 2009
    ..Mechanisms of resistance to endocrine interventions and trials exploring strategies to overcome them will also be discussed...
  27. ncbi request reprint Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer
    S J Stanway
    Imperial College London, London, UK
    Anticancer Res 31:1367-72. 2011
    ..In contrast, little is known about the effects of aromatase inhibitors or anti-estrogens on STS activity or serum androgen levels...
  28. doi request reprint Is the presence of small volume disease in the sentinel node an indication for axillary clearance?
    Darren K Patten
    Department of Biosurgery and Surgical Oncology, St Mary s Hospital, Imperial College Healthcare NHS Trust, London, UK
    Breast 22:70-3. 2013
    ..Given the fact that axillary lymphadenectomy is associated with a 5-25% risk of lymphoedema, we propose that a policy of close follow up should be adopted in these patients rather than axillary lymphadenectomy...
  29. ncbi request reprint Targeted histone deacetylase inhibition for cancer prevention and therapy
    Carlo Palmieri
    Department of Cancer Medicine, 7th Floor MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Prog Drug Res 63:147-81. 2005
  30. doi request reprint Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer
    Flora Stavridi
    Department of Medical Oncology, St George s Hospital, Blackshaw Road, London, SW18 0QT, UK
    Expert Rev Anticancer Ther 8:1859-69. 2008
    ..The favorable cardiac safety profile of NPLD may allow it to be combined with newer therapies, such as trastuzumab...
  31. doi request reprint Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients
    Laura M Kenny
    Department of Oncology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, United Kingdom
    J Nucl Med 49:879-86. 2008
    ....
  32. ncbi request reprint Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial
    Nicola M Neary
    Department of Metabolic Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom W12 0NN
    J Clin Endocrinol Metab 89:2832-6. 2004
    ..The stimulatory effects of ghrelin on food intake and meal appreciation seen in this preliminary study suggest that ghrelin could be an effective treatment for cancer anorexia and possibly for appetite loss in other patient groups...
  33. doi request reprint Severe thrombocytopenia induced by a single infusion of trastuzumab
    Omi Parikh
    Royal Preston Hospital, London, UK
    Clin Breast Cancer 8:285-6. 2008
    ..This case highlights a serious and potentially life-threatening complication with the use of single-agent trastuzumab...
  34. ncbi request reprint Management and outcome of healthy women with a persistently elevated beta-hCG
    Carlo Palmieri
    Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London, UK
    Gynecol Oncol 106:35-43. 2007
    ..Here we report the United Kingdom experience of patients with an elevated beta-hCG of initial uncertain cause and provide a clinical algorithm for the management of such cases...
  35. ncbi request reprint The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival
    Carlo Palmieri
    Department of Cancer Medicine, Cancer Cell Biology Group, Cancer Research UK Laboratories, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Clin Cancer Res 10:2421-8. 2004
    ..ER beta cx, a variant of ER beta, has a dominant-negative effect over ER alpha, and its expression thought to modulate response to endocrine treatment may represent a predictor of response to endocrine therapy...
  36. doi request reprint Angiosarcoma of the breast following surgery and radiotherapy for breast cancer
    Rachel Abbott
    Guy s and St Thomas Hospitals NHS Trust, London, UK
    Nat Clin Pract Oncol 5:727-36. 2008
    ..Overall survival, however, remains poor...
  37. ncbi request reprint Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells
    C Palmieri
    Cancer Research UK Laboratories, Department of Cancer Medicine, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    J Endocrinol 177:65-81. 2003
    ..In summary, our findings suggest that FGF7 is a paracrine growth factor in the breast. FGF7 is produced by the breast stromal fibroblasts and has profound proliferative and morphogenic roles on both epithelial and myoepithelial cells...
  38. ncbi request reprint Resolution of late-onset asthma following high-dose chemotherapy
    C Palmieri
    Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London, UK
    Bone Marrow Transplant 32:847-8. 2003
    ..As far as the authors are aware this is the first reported case...
  39. pmc Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
    M J Slade
    1Department of Oncology, Imperial College, MRC Cyclotron Building, London W12 0NN, UK
    Br J Cancer 100:160-6. 2009
    ....
  40. ncbi request reprint Estrogen receptor beta in breast cancer
    C Palmieri
    Department of Cancer Medicine, Cancer Cell Biology Group, Cancer Research Campaign Laboratories, Imperial College School of Medicine, Hammersmith Campus, Du Cane Road, London W12 ONN, UK
    Endocr Relat Cancer 9:1-13. 2002
    ....
  41. ncbi request reprint Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
    W Heller
    Department of Medical Oncology, Cancer Research UK Laboratories, Faculty of Medicine, Imperial College London, London W6 8RF, UK
    Oncol Rep 17:253-9. 2007
    ....
  42. pmc Therapeutic monoclonal antibodies in oncology
    Adam P Levene
    Department of Cardiology, Leeds General Infirmary, Leeds LS1 3EX, UK
    J R Soc Med 98:146-52. 2005
  43. ncbi request reprint Palifermin and chemotherapy-induced oral mucositis
    Carlo Palmieri
    N Engl J Med 352:1264-5; author reply 1264-5. 2005
  44. ncbi request reprint Gene-expression profiling and identification of patients at high risk of breast cancer
    Carlo Palmieri
    Lancet 360:173; author reply 174. 2002